TY - JOUR
T1 - Two-year outcomes of statin therapy in patients with acute myocardial infarction with or without dyslipidemia after percutaneous coronary intervention in the era of new-generation drug-eluting stents within Korean population
T2 - Data from the Korea Acute Myocardial Infarction Registry
AU - Kim, Yong Hoon
AU - Her, Ae Young
AU - Jeong, Myung Ho
AU - Kim, Byeong Keuk
AU - Shin, Dong Ho
AU - Kim, Jung Sun
AU - Ko, Young Guk
AU - Choi, Donghoon
AU - Hong, Myeong Ki
AU - Jang, Yangsoo
N1 - Funding Information:
This research was supported by a fund (2016-ER6304-02) by Research of Korea Centers for Disease Control and Prevention.
Publisher Copyright:
© 2018 Wiley Periodicals, Inc.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Background: Limited studies focused on long-term outcomes of statin therapy in patients with acute myocardial infarction (AMI) with or without dyslipidemia after percutaneous coronary intervention (PCI) in the era of new-generation drug-eluting stents (DES). We thought to investigate 2-year clinical outcomes of statin therapy in these patients. Methods: A total of 18,137 eligible AMI patients (from the Korea AMI Registry [KAMIR]) were finally enrolled and divided into four groups according to the presence or absence of dyslipidemia and statin therapy (dyslipidemia+/statin− [group A, 309 patients], dyslipidemia+/statin+ [group B, 2094 patients], dyslipidemia−/statin– [group C, 672 patients], dyslipidemia−/statin+ [group D, 15062 patients]). The primary outcome was major adverse cardiac event (MACE) defined as all-cause death, myocardial infarction (MI) and revascularization. Results: During the 2-year follow-up period, the cumulative incidence of MACE in the group A was higher than the group B (adjusted hazard ratio [HR], 2.207; 95% confidence interval (CI), 1.098–3.743; p =.024) and the group D (adjusted HR, 2.110; 95% CI, 1.240–3.593, p =.006). This significantly increased incidence of MACE caused by the higher cumulative incidences of all-cause death and cardiac death (CD) in the group A compared with groups B and D. However, the cumulative incidences of MI and revascularization were not significantly different among these four groups. Conclusion: Statin therapy demonstrated significantly reduced incidences of MACE, all-cause death and CD compared with non-users after PCI in AMI patients with or without dyslipidemia during 2-year follow-up period in the era of new-generation DES.
AB - Background: Limited studies focused on long-term outcomes of statin therapy in patients with acute myocardial infarction (AMI) with or without dyslipidemia after percutaneous coronary intervention (PCI) in the era of new-generation drug-eluting stents (DES). We thought to investigate 2-year clinical outcomes of statin therapy in these patients. Methods: A total of 18,137 eligible AMI patients (from the Korea AMI Registry [KAMIR]) were finally enrolled and divided into four groups according to the presence or absence of dyslipidemia and statin therapy (dyslipidemia+/statin− [group A, 309 patients], dyslipidemia+/statin+ [group B, 2094 patients], dyslipidemia−/statin– [group C, 672 patients], dyslipidemia−/statin+ [group D, 15062 patients]). The primary outcome was major adverse cardiac event (MACE) defined as all-cause death, myocardial infarction (MI) and revascularization. Results: During the 2-year follow-up period, the cumulative incidence of MACE in the group A was higher than the group B (adjusted hazard ratio [HR], 2.207; 95% confidence interval (CI), 1.098–3.743; p =.024) and the group D (adjusted HR, 2.110; 95% CI, 1.240–3.593, p =.006). This significantly increased incidence of MACE caused by the higher cumulative incidences of all-cause death and cardiac death (CD) in the group A compared with groups B and D. However, the cumulative incidences of MI and revascularization were not significantly different among these four groups. Conclusion: Statin therapy demonstrated significantly reduced incidences of MACE, all-cause death and CD compared with non-users after PCI in AMI patients with or without dyslipidemia during 2-year follow-up period in the era of new-generation DES.
UR - http://www.scopus.com/inward/record.url?scp=85057478553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057478553&partnerID=8YFLogxK
U2 - 10.1002/ccd.27985
DO - 10.1002/ccd.27985
M3 - Article
C2 - 30474346
AN - SCOPUS:85057478553
VL - 93
SP - 1264
EP - 1275
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
SN - 1522-1946
IS - 7
ER -